



# **MASTITISRESISTANTPRO**<sup>®</sup>



# Avoid costly mastitis cases and save money

A case of clinical mastitis in the first 30 days of lactation can result in an economic loss of \$444 (\$128 in direct costs and \$316 in indirect costs), including loss of future milk production, premature culling and replacement loss, and future reproductive loss<sup>1</sup>.



# Reduce waste milk and keep valuable replacements in the herd

Mastitis is a leading reason for voluntary culling, especially in cows beyond the first lactation. The most common clinical disease in cows reported by producers is mastitis (24.8 percent of cows)<sup>2</sup>. Fewer mastitis cases means less discarded milk and reduced treatment cost in all management systems.



# Lower antimicrobial use

Over twenty percent of all lactating dairy cows receive antibiotic therapy for clinical mastitis each year and many cows receive intramammary infusions as they go dry<sup>2</sup>. Improving genetic merit for mastitis resistance will reduce use of antimicrobials.



# A genetic solution to mastitis resistance

Sires that excel in multiple indicators of mastitis resistance are more likely to deliver genetic improvement. Mastitis ResistantPRO uses a combination of CDCB Mastitis Resistance, CDCB Somatic Cell Score (SCS) and Zoetis Mastitis Resistance genomic evaluations.



Mastitis ResistantPRO is a registered trademark of Select Sires Inc. "Your Success Our Passion. and the Select Sires logo are registered trademarks of Select Sires Inc., Plain City, Ohio. <sup>1</sup>Preventive Veterinary Medicine, Vol. 122, Issue 3, 12/2015, Pages 257-264. <sup>2</sup>National Animal Health Monitoring System, 2014. 12/2023 CDCB/Zoetis